Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan added to steroid pulse therapy plus tonsillectomy for IgA nephropathy
ACTRN12610000516088Phase 3Recruiting
- Sponsor
- University of the Ryukyus
- Start
- Apr 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of candesartan in IgA nephropathy (IgAN) (2 arms), sponsored by University of the Ryukyus. Primary endpoints: Remission rate of proteinuria and hematuria at 24 months and Reduction rate of proteinuria and hematuria at 24 months. Started Apr 2007; status: recruiting.
02
Drugs
candesartan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ACTRN12610000516088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000516088.